Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint
作者： Dario Cattaneo , Sara Baldelli , Simone Castoldi , Nitin Charbe , Valeria Cozzi
DOI: 10.1097/QAD.0000000000000440
关键词:
摘要: We document our experience with therapeutic drug monitoring (TDM) of antiretroviral agents (1807 determinations) carried out as day-by-day clinical practice for the optimization dosing in HIV-infected patients. A significant proportion patients had lopinavir, atazanavir and nevirapine trough concentrations exceeding upper threshold. Further studies are needed to identify good candidates/drugs TDM, eventually allowing selection who may benefit from TDM-driven adjustments antiretrovirals dosage.
elsevier.com
wkhealth.com参考文章(23)
Rustin D. Crutchley, Qing Ma, Adel Sulaiman, Jill Hochreitter, Gene D. Morse, Within-Patient Atazanavir Trough Concentration Monitoring in HIV-1-Infected Patients Journal of Pharmacy Practice. ,vol. 24, pp. 216- 222 ,(2011) , 10.1177/0897190010380923
Diana M. Brainard, Larissa A. Wenning, Julie A. Stone, John A. Wagner, Marian Iwamoto, Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. The Journal of Clinical Pharmacology. ,vol. 51, pp. 1376- 1402 ,(2011) , 10.1177/0091270010387428
Dario Cattaneo, Diego Ripamonti, Cristina Gervasoni, Simona Landonio, Paola Meraviglia, Sara Baldelli, Valeria Cozzi, Serena Fucile, Emilio Clementi, Limited sampling strategies for the estimation of raltegravir daily exposure in HIV-infected patients The Journal of Clinical Pharmacology. ,vol. 52, pp. 440- 445 ,(2012) , 10.1177/0091270010395939
Félix Gutiérrez, Sergio Padilla, Andrés Navarro, Mar Masiá, Ildefonso Hernández, José Ramos, Angel Esteban, Alberto Martin-Hidalgo, Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens Journal of Acquired Immune Deficiency Syndromes. ,vol. 33, pp. 594- 600 ,(2003) , 10.1097/00126334-200308150-00007
Keith W Crawford, David H Brown Ripin, Andrew D Levin, Jennifer R Campbell, Charles Flexner, None, Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement Lancet Infectious Diseases. ,vol. 12, pp. 550- 560 ,(2012) , 10.1016/S1473-3099(12)70134-2
D. Cattaneo, C. Gervasoni, P. Meraviglia, S. Landonio, S. Fucile, V. Cozzi, S. Baldelli, M. Pellegrini, M. Galli, E. Clementi, Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects Journal of Antimicrobial Chemotherapy. ,vol. 67, pp. 460- 464 ,(2012) , 10.1093/JAC/DKR498
John O’Quigley, Mark Conaway, Continual Reassessment and Related Dose-Finding Designs Statistical Science. ,vol. 25, pp. 202- 216 ,(2010) , 10.1214/10-STS332
D. González de Requena, S. Bonora, S. Garazzino, M. Sciandra, A. D'Avolio, R. Raiteri, R. Marrone, M. Boffito, F. G. De Rosa, A. Sinicco, G. Di Perri, Nevirapine Plasma Exposure Affects both Durability of Viral Suppression and Selection of Nevirapine Primary Resistance Mutations in a Clinical Setting Antimicrobial Agents and Chemotherapy. ,vol. 49, pp. 3966- 3969 ,(2005) , 10.1128/AAC.49.9.3966-3969.2005
Aurélie Fayet Mello, Thierry Buclin, Laurent A Decosterd, Cécile Delhumeau, Julia di Iulio, Alessandra Fleurent, Marie-Paule Schneider, Matthias Cavassini, Amalio Telenti, Bernard Hirschel, Alexandra Calmy, Successful efavirenz dose reduction guided by therapeutic drug monitoring. Antiviral Therapy. ,vol. 16, pp. 189- 197 ,(2011) , 10.3851/IMP1742